Drugs / EVO756
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07616128 | Jun 2026 → Oct 2027 expected | migraine disorder | Evommune, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07150845 | Aug 2025 → Jul 2026 overdue | atopic eczema | Evommune, Inc. | Active not recruiting | Missed primary |
| Phase 2 | NCT06873516 | Mar 2025 → May 2026 | chronic idiopathic urticaria | Evommune, Inc. | Completed | Missed primary |
| Phase 2 | NCT06603220 | Aug 2024 → May 2025 | chronic inducible urticaria | Evommune, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Evommune, Inc. | Results Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis evommune.com ↗
The Phase 2b trial enrolled 121 adults with moderate-to-severe AD over a 12-week treatment period, with follow-up through Week 14, and did not meet the primary and secondary endpoints in any of the doses studied. |
| 2026-06-29 | Evommune, Inc. | Results Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria evommune.com ↗
The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. |
| 2025-09-19 | Evommune, Inc. | Results Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress evommune.com ↗
The full Phase 2 data presented today highlight EVO756's differentiated mast cell dual mechanism, with responses observed as early as one week and after four weeks of oral treatment. |
| 2025-05-28 | Evommune, Inc. | Results Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile evommune.com ↗
PALO ALTO, Calif. , May 28, 2025 /PRNewswire/ -- Evommune, Inc., a clinical-stage biotechnology company developing innovative therapies for chronic inflammatory diseases, today announced positive top-line data from its Phase 2 trial of EVO756 in adults with chronic inducible urticaria (CIndU). |
| 2024-12-04 | Evommune, Inc. | Results Evommune Presents Positive Clinical Results of its MRGPRX2 Antagonist (EVO756) at the 7th GA²LEN Global Urticaria Forum evommune.com ↗
Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today presented the complete data set from its first-in-human proof-of-concept (POC) trial with EVO756 at the 7th GA²LEN Global Urticaria Forum in Berlin, Germany. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVO756 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06603220 ↗ |
| Route | Oral | “Oral EVO756, 300 mg once daily” NCT06603220 ↗ |